Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Significant Increase in Short Interest

Posted by Brenda Bartman on Aug 28th, 2026

Xenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report) saw a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 45,169 shares, an increase of 299.3% from the July 30th total of 11,313 shares. Based on an average daily trading volume, of 111,557 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.1% of the company’s shares are short sold.

Xenetic Biosciences Stock Down 1.5%

Shares of XBIO stock traded down $0.06 during trading on Friday, reaching $3.91. The company’s stock had a trading volume of 10,324 shares, compared to its average volume of 26,706. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93. The business has a fifty day moving average price of $2.98 and a 200-day moving average price of $2.92. The company has a market cap of $8.95 million, a price-to-earnings ratio of -3.37 and a beta of 2.10.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.The firm had revenue of $0.66 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Stock Report on XBIO

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC grew its position in Xenetic Biosciences, Inc. (NASDAQ:XBIO – Free Report) by 516.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 as of its most recent filing with the SEC. 15.12% of the stock is currently owned by institutional investors and hedge funds.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.